Sunday, July 20, 2025 4:22:40 PM
Jerry,
You linked the Q1 2025 10-Q and claimed the quote about “Flaskworks EDEN” doesn’t exist, and used that to accuse me of lying.
Let’s be clear: your own link proves my point.
The 10-Q explicitly states:
“The Flaskworks team and Advent BioServices continued to work with the specialized contractor on the development of the GMP-grade units of the Flaskworks system.”
“The Company expects the Grade C cleanrooms to be important for scale-up, as they will accommodate the ‘closed’ Flaskworks system…”
Those are direct quotes from the document you posted.
As for the quote you’re trying to debunk
“We are working with Flaskworks to prepare comparability testing and validation protocols for submission to the regulators.”
You’re right that this exact phrasing doesn’t appear in the 10-K or ASM transcripts. But that doesn’t make it “fabricated.” It’s a paraphrase, drawn from multiple filings that clearly mention Flaskworks development, GMP adaptation, and regulatory preparation.
Unless you’re prepared to claim NWBO is building GMP-grade automated systems, cleanrooms, and scaling protocols without ever intending to submit them to regulators, the distinction you’re trying to exploit here is meaningless.
I don’t have time to spoon-feed reading comprehension across 300 pages of filings.But if you’re going to call people liars, make sure your own links don’t prove them right.
And if we’re trading accusations, I’ll happily ask why your posts consistently mirror talking points from known biotech shills, including AF. If I’m being accused of fabrication, I get to question your motives too.
You linked the Q1 2025 10-Q and claimed the quote about “Flaskworks EDEN” doesn’t exist, and used that to accuse me of lying.
Let’s be clear: your own link proves my point.
The 10-Q explicitly states:
“The Flaskworks team and Advent BioServices continued to work with the specialized contractor on the development of the GMP-grade units of the Flaskworks system.”
“The Company expects the Grade C cleanrooms to be important for scale-up, as they will accommodate the ‘closed’ Flaskworks system…”
Those are direct quotes from the document you posted.
As for the quote you’re trying to debunk
“We are working with Flaskworks to prepare comparability testing and validation protocols for submission to the regulators.”
You’re right that this exact phrasing doesn’t appear in the 10-K or ASM transcripts. But that doesn’t make it “fabricated.” It’s a paraphrase, drawn from multiple filings that clearly mention Flaskworks development, GMP adaptation, and regulatory preparation.
Unless you’re prepared to claim NWBO is building GMP-grade automated systems, cleanrooms, and scaling protocols without ever intending to submit them to regulators, the distinction you’re trying to exploit here is meaningless.
I don’t have time to spoon-feed reading comprehension across 300 pages of filings.But if you’re going to call people liars, make sure your own links don’t prove them right.
And if we’re trading accusations, I’ll happily ask why your posts consistently mirror talking points from known biotech shills, including AF. If I’m being accused of fabrication, I get to question your motives too.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
